

Edgar Filing: HOLLIS EDEN PHARMACEUTICALS INC /DE/ - Form SC 13G

HOLLIS EDEN PHARMACEUTICALS INC /DE/
Form SC 13G
June 06, 2005

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN THE STATEMENTS FILED
PURSUANT TO RULES 13d-1(b) (c), AND (d) AND AMENDMENTS THERETO
FILED PURSUANT TO RULE 13d-2(b)

(Amendment No.)*

Hollis-Eden Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value \$0.01 per share

(Title of Class of Securities)

435902101

(CUSIP Number)

June 2, 2005

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13G

CUSIP NO. 435902101

Page 2 of 8

1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

Cranshire Capital, L.P.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
(b)

3 SEC USE ONLY

Edgar Filing: HOLLIS EDEN PHARMACEUTICALS INC /DE/ - Form SC 13G

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Illinois

NUMBER OF 5 SOLE VOTING POWER

SHARES 1,333,333 shares of Common Stock (See Item 4)

BENEFICIALLY 6 SHARED VOTING POWER

OWNED BY None

EACH 7 SOLE DISPOSITIVE POWER

REPORTING 1,333,333 shares of Common Stock (See Item 4)

PERSON 8 SHARED DISPOSITIVE POWER

WITH None

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,333,333 shares of Common Stock (See Item 4)

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

[X]

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.9% (See Item 4)

12 TYPE OF REPORTING PERSON

PN

SCHEDULE 13G

CUSIP NO. 435902101

Page 3 of 8

1 NAMES OF REPORTING PERSONS

I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)

Downsview Capital, Inc.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) []

(b) []

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

Illinois

NUMBER OF 5 SOLE VOTING POWER

SHARES 1,333,333 shares of Common Stock (See Item 4)

BENEFICIALLY 6 SHARED VOTING POWER

Edgar Filing: HOLLIS EDEN PHARMACEUTICALS INC /DE/ - Form SC 13G

1,333,333 shares of Common Stock (See Item 4)

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

[X]

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.9% (See Item 4)

12 TYPE OF REPORTING PERSON

IN

SCHEDULE 13G

CUSIP NO. 435902101

Page 5 of 8

Item 1(a). Name of Issuer:

Hollis-Eden Pharmaceuticals, Inc., a Delaware corporation (the "Issuer")

Item 1(b). Address of Issuer's Principal Executive Offices:

4435 Eastgate Mall, Suite 400
San Diego, California 92121

Items 2(a), (b) and (c). Name of Persons Filing, Address of Principal Business Office and Citizenship:

This Schedule 13G is being filed on behalf of (i) Cranshire Capital, L.P., an Illinois limited partnership ("Cranshire"), (ii) Downsview Capital, Inc., an Illinois corporation ("Downsview") and (iii) Mitchell P. Kopin, an individual who is a citizen of the U.S.A. ("Kopin," together with Cranshire and Downsview, the "Reporting Persons").

The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

The principal business office of each of the Reporting Persons is 666 Dundee Road, Suite 1901, Northbrook, Illinois, 60062.

Item 2(d). Title of Class of Securities:

Common Stock, par value \$0.01 per share, of the Issuer (the "Common Stock")

Item 2(e). CUSIP Number:

435902101

Item 3. Not applicable.

Item 4. Ownership.

Edgar Filing: HOLLIS EDEN PHARMACEUTICALS INC /DE/ - Form SC 13G

(a) Amount beneficially owned:

1,333,333 shares of Common Stock*

(b) Percent of class:

Based on 19,298,913 shares of Common Stock of the Issuer outstanding as of June 2, 2005 (as set forth in the Issuer's Form 424(B) (5) filed on June 2, 2005),

SCHEDULE 13G

CUSIP NO. 435902101

Page 6 of 8

Cranshire holds approximately 6.9% of the issued and outstanding Common Stock of the Issuer.

(c) Number of shares to which such person has:

- (i) Sole power to vote or direct the vote: 1,333,333 shares of Common Stock*
- (ii) Shared power to vote or direct the vote: None
- (iii) Sole power to dispose or to direct the disposition of: 1,333,333 shares of Common Stock*
- (iv) Shared power to dispose of or direct the disposition of: None

*Cranshire beneficially owns an aggregate of 1,333,333 shares of Common Stock. The beneficial ownership of the Reporting Persons excludes certain shares of Common Stock issuable upon the exercise of warrants held by Cranshire. Such warrants issued to Cranshire contain exercise caps which prohibit the holder of the warrants from exercising such warrants to the extent that giving effect to such exercise, such holder would beneficially own in excess of 4.99% of the Issuer's outstanding Common Stock (determined in accordance with Section 13(d) of the Securities Exchange Act of 1934).

Because (i) Downsview is the general partner of Cranshire and (ii) Kopin is the holder of 100% of the issued and outstanding shares of Downsview and is the president thereof, each of Downsview and Kopin are considered to share the power to vote or direct the vote of, and the power to dispose or direct the disposition of, the shares of Common Stock which Cranshire beneficially owns. Each of Downsview and Kopin disclaim beneficial ownership of the reported securities except to the extent of each of their respective pecuniary interests therein, and this statement on Schedule 13G shall not be construed as an admission that each of the Reporting Persons is the beneficial owner of the Common Stock covered by such statement.

Item 5. Ownership of Five Percent or Less of a Class.

Not Applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

Edgar Filing: HOLLIS EDEN PHARMACEUTICALS INC /DE/ - Form SC 13G

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported By the Parent Holding Company.

Not Applicable.

SCHEDULE 13G

CUSIP NO. 435902101

Page 7 of 8

Item 8. Identification and Classification of Members of the Group.

Not Applicable.

Item 9. Notice of Dissolution of a Group.

Not Applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SCHEDULE 13G

CUSIP NO. 435902101

Page 8 of 8

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: June 6, 2005

CRANSHIRE CAPITAL, L.P.

By: Downsview Capital, Inc.,
its general partner

By:/s/ Mitchell P. Kopin

Mitchell P. Kopin, President

DOWNSVIEW CAPITAL, INC.

By:/s/ Mitchell P. Kopin

Mitchell P. Kopin, President

/s/ Mitchell P. Kopin

Mitchell P. Kopin

Edgar Filing: HOLLIS EDEN PHARMACEUTICALS INC /DE/ - Form SC 13G

SCHEDULE 13G

CUSIP NO. 435902101

Exhibit 1

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to 1,333,333 shares of Common Stock of Hollis-Eden Pharmaceuticals, Inc., and further agree that this Joint Filing Agreement shall be included as an exhibit to such joint filings.

The undersigned further agree that each party hereto is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein; provided, however, that no party is responsible for the completeness or accuracy of the information concerning any other party making the filing, unless such party knows or has reason to believe that such information is inaccurate.

IN WITNESS WHEREOF, the parties have executed this Joint Filing Agreement on June 6, 2005.

CRANSHIRE CAPITAL, L.P.

By: Downsvie Capital, Inc.,
its general partner

By:/s/ Mitchell P. Kopin

Mitchell P. Kopin, President

DOWNSVIEW CAPITAL, INC.

By:/s/ Mitchell P. Kopin

Mitchell P. Kopin, President

/s/ Mitchell P. Kopin

Mitchell P. Kopin